Alnylam Pharmaceuticals (ALNY) Projected to Post Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Alnylam Pharmaceuticals to post earnings of ($0.55) per share and revenue of $584.32 million for the quarter. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, analysts expect Alnylam Pharmaceuticals to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alnylam Pharmaceuticals Trading Up 0.9 %

NASDAQ ALNY traded up $2.34 on Tuesday, reaching $257.19. The company had a trading volume of 941,496 shares, compared to its average volume of 879,806. The firm has a market cap of $33.46 billion, a price-to-earnings ratio of -118.52 and a beta of 0.30. Alnylam Pharmaceuticals has a fifty-two week low of $143.81 and a fifty-two week high of $304.39. The business has a 50 day moving average of $247.55 and a two-hundred day moving average of $255.64. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares of the company's stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,392 shares of company stock valued at $1,875,627. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

An institutional investor recently bought a new position in Alnylam Pharmaceuticals stock. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,032 shares of the biopharmaceutical company's stock, valued at approximately $243,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ALNY. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. HC Wainwright restated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Citigroup increased their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Finally, StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.